BGLC
BioNexus Gene Lab Corp
3월 13일 4:00 PM ET (한국 3/14 05:00)
$2.24
+0.01 ▲ +0.45%
🌙 3월 13일 5:30 PM ET (한국 3/14 06:30)
$2.32
+0.08 ▲ +3.57%
| Index | - | P/E | - | EPS (ttm) | -1.28 | Insider Own | 35.59% | Shs Outstand | 0.00B | Perf Week | -10.4% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.00B | Perf Month | 14.87% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 2.66% | Short Float | 2.35% | Perf Quarter | -48.39% |
| Income | -0.00B | P/S | 0.42 | EPS this Y | - | Inst Trans | 18.65% | Short Ratio | 1.17 | Perf Half Y | -47.91% |
| Sales | 0.01B | P/B | 0.59 | EPS next 5Y | - | ROA | -24.68% | Short Interest | 0.03M | Perf YTD | -43.29% |
| Book/sh | 3.79 | P/C | 1.39 | EPS past 3/5Y | - -21.27% | ROE | -28.35% | 52W High | -85.64% ($15.60) | Perf Year | -36.18% |
| Cash/sh | 1.61 | P/FCF | - | Sales past 3/5Y | -10.72% 137.09% | ROIC | -33.08% | 52W Low | 16.67% ($1.92) | Perf 3Y | -97.08% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -145.75% | Gross Margin | 14.46% | Volatility(W/M) | 7.95% 6.16% | Perf 5Y | -99.07% |
| Dividend TTM | - | EV/Sales | 0.14 | Sales Y/Y TTM | 2.22% | Oper. Margin | -16.15% | ATR (14) | 0.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.81 | EPS Q/Q | 47.3% | Profit Margin | -24.27% | RSI (14) | 39.1 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.3 | Sales Q/Q | -3.29% | SMA20 | -6.88% ($2.41) | Beta | 2.3 | Target Price | - |
| Payout | - | Debt/Eq | 0.03 | Earnings | - | SMA50 | -20.43% ($2.82) | Rel Volume | 0.21 | Prev Close | $2.23 |
| Employees | 30 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | - | SMA200 | -48.4% ($4.34) | Avg Volume(3M) | 0.02M | Price | $2.24 |
| IPO | 2020/9/16 | Option/Short | No/Yes | Trades | 35 | Volume | 4,829 | Change | 0.45% |
뉴스 로딩 중...